

Title (en)  
CD3 ANTIGEN BINDING FRAGMENTS AND COMPOSITIONS COMPRISING SAME

Title (de)  
CD3-ANTIGEN-BINDENDE FRAGMENTE UND ZUSAMMENSETZUNGEN DAMIT

Title (fr)  
FRAGMENTS DE LIAISON À L'ANTIGÈNE CD3 ET COMPOSITIONS LES COMPRENANT

Publication  
**EP 3990497 A4 20230719 (EN)**

Application  
**EP 20833432 A 20200625**

Priority  
• US 201962866746 P 20190626  
• US 202063041059 P 20200618  
• US 2020039673 W 20200625

Abstract (en)  
[origin: WO2020264200A1] This disclosure relates to compositions having an antibody binding fragment that specifically binds to CD3 or an epitope thereof. Some embodiments include compositions and antibody binding fragments with increased stability. Bispecific fusion proteins including such antibody-binding fragments are also disclosed.

IPC 8 full level  
**C07K 16/28** (2006.01); **A61K 39/00** (2006.01); **A61K 39/395** (2006.01); **A61P 35/00** (2006.01); **C07K 16/30** (2006.01); **C07K 16/32** (2006.01); **C07K 16/46** (2006.01)

CPC (source: AU EP IL KR US)  
**A61K 39/461** (2023.05 - AU EP IL KR); **A61K 39/464404** (2023.05 - AU EP IL KR); **A61K 39/464406** (2023.05 - AU EP IL KR); **A61P 35/00** (2018.01 - AU EP IL KR US); **C07K 14/485** (2013.01 - IL); **C07K 16/2809** (2013.01 - AU EP IL KR US); **C07K 16/2863** (2013.01 - AU EP IL); **C07K 16/30** (2013.01 - EP IL US); **C07K 16/32** (2013.01 - EP IL KR US); **C07K 16/468** (2013.01 - AU EP IL); **C12N 15/70** (2013.01 - KR); **A61K 39/00** (2013.01 - AU EP IL KR US); **A61K 2039/505** (2013.01 - AU EP IL KR); **A61K 2239/31** (2023.05 - AU EP IL KR); **A61K 2239/49** (2023.05 - AU EP IL KR); **A61K 2239/50** (2023.05 - AU EP IL KR); **A61K 2239/59** (2023.05 - AU EP IL KR); **C07K 14/485** (2013.01 - AU); **C07K 2317/24** (2013.01 - US); **C07K 2317/31** (2013.01 - AU EP IL KR US); **C07K 2317/33** (2013.01 - EP IL KR); **C07K 2317/565** (2013.01 - IL US); **C07K 2317/567** (2013.01 - IL US); **C07K 2317/622** (2013.01 - EP IL KR); **C07K 2317/92** (2013.01 - IL US); **C07K 2317/94** (2013.01 - AU EP IL KR US); **C07K 2319/00** (2013.01 - US); **C07K 2319/31** (2013.01 - EP IL KR); **C07K 2319/50** (2013.01 - EP IL KR); **C07K 2319/95** (2013.01 - AU IL)

Citation (search report)  
• [Y] WO 2012158818 A2 20121122 - FABION PHARMACEUTICALS INC [US], et al  
• [Y] WO 2016014974 A2 20160128 - CYTOMX THERAPEUTICS INC [US]  
• [XP] WO 2007042261 A9 20200507 - MICROMET AG [DE], et al  
• [E] WO 2021097186 A1 20210520 - AMUNIX PHARMACEUTICALS INC [US]  
• See also references of WO 2020264200A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2020264200 A1 20201230**; AU 2020308868 A1 20220120; BR 112021026089 A2 20220322; CA 3143519 A1 20201230; CL 2021003448 A1 20220909; CN 115175933 A 20221011; CO 2022000406 A2 20220531; CR 20210628 A 20220322; EC SP22005986 A 20220429; EP 3990497 A1 20220504; EP 3990497 A4 20230719; IL 289102 A 20220201; JP 2022537824 A 20220830; KR 20220038068 A 20220325; MX 2021015880 A 20220322; PE 20220600 A1 20220425; US 2021054077 A1 20210225; US 2023121775 A1 20230420

DOCDB simple family (application)  
**US 2020039673 W 20200625**; AU 2020308868 A 20200625; BR 112021026089 A 20200625; CA 3143519 A 20200625; CL 2021003448 A 20211222; CN 202080061316 A 20200625; CO 2022000406 A 20220119; CR 20210628 A 20200625; EC DI202205986 A 20220125; EP 20833432 A 20200625; IL 28910221 A 20211219; JP 2021576275 A 20200625; KR 20227002573 A 20200625; MX 2021015880 A 20200625; PE 2021002228 A 20200625; US 202016996899 A 20200819; US 202017621993 A 20200625